Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Diane Reidy-Lagunes

GI Oncology · Duke University

View

Dr. Tyler Johnson

GI Oncology · Stanford

View

Dr. Thorvardur Halfdanarson

GI Oncology · Mayo Clinic Rochester

View

Dr. Linette Bosques

GI Oncology · DFCI/MGB

View

Dr. Shikha Jain

GI Oncology · University Illinois

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    JCDr. James Cleary
    Leading Voice

    Dr. James Cleary

    Hematology & Oncology · Gastrointestinal Oncology
    Dana-Farber Cancer Institute
    jamesc

    Research

    MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response

    2026

    Via Clin Cancer Res

    Research

    A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2

    2026

    Via Clin Cancer Res

    Research

    Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial

    2026

    Via Nat Cancer

    Research

    CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer

    2026

    Via Cell

    Research

    NCCN Guidelines® Insights: Hepatocellular Carcinoma, Version 2.2026

    2026

    Via J Natl Compr Canc Netw

    Research

    A Phase 1 Trial of Low-dose Gemcitabine Combined with ATR Inhibitor Elimusertib for Advanced Solid Tumors

    2026

    Via Cancer Res Commun

    Research

    A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

    2025

    Via Ann Oncol

    Research

    A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

    2025

    Via Cancer Immunology Research

    Research

    A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors

    2025

    Via Clinical Cancer Research

    Research

    CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

    2025

    Via BJC Reports

    Research

    Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition

    2025

    Via Science

    Research

    Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets

    2025

    Via Cancer Discovery

    Research

    Quality indicators and patient outcome measures for palliative care in cancer patients: a systematic review

    2025

    Via Ecancermedicalscience

    Research

    Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation

    2025

    Via Gastroenterology

    Research

    Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

    2025

    Via Journal of the National Comprehensive Cancer Network